Peritoneal Dialysis (PD)UPLIFT-PD CORRNCT07477210
Examine the Epidemiology and Outcomes of Transitions From PD-to-HD in Canada
An observational study of Peritoneal Dialysis (PD) and Hemodialysis, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
Trial summary
Transitions from peritoneal dialysis to hemodialysis are common during kidney replacement therapy and may be associated with adverse outcomes. However, the incidence, predictors, and outcomes of PD-to-HD transitions at a national level remain incompletely characterized. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Peritoneal Dialysis (PD), Hemodialysis, Kidney Replacement Therapy
- How many people
- 17,000 participants
- Where
- 1 siteCanada
- Study dates
- 1 Jan 2005to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis for at least 30 consecutive days, identified using the Canadian Organ Replacement Register (CORR) and linked administrative databases.
Who may be able to join
- Adults (≥18 years)
- Dialysis initiation in Canada between January 1, 2005 and December 31, 2018
- Peritoneal dialysis duration >30 consecutive days
Who cannot join
- Dialysis initiation in Quebec or Manitoba during the study period
- Dialysis initiation in a foreign country
- Missing data on initial dialysis modality
- Pre-emptive kidney transplantation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis, Epidemiology (Phase 1)
Transitions from peritoneal dialysis to hemodialysis are common during kidney replacement therapy and may be associated with adverse outcomes. However, the incidence, predictors, and outcomes of PD-to-HD transitions at a national level remain incompletely characterized.
This study will use Canadian dialysis and hospitalization databases to examine the epidemiology and outcomes of PD-to-HD transitions among adults initiating dialysis in Canada. The study will evaluate transition incidence, predictors, and post-transition outcomes including mortality, transplantation, modality changes, and hospitalizations.
- Keywords
- Transition, Transfer to hemodialysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patient receiving peritoneal dialysis with transfer to hemodialysis | Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis and experience a transfer to hemodialysis for 2 or more consecutive days. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of transfer from peritoneal dialysis to hemodialysis
Measured as cumulative incidence and incidence rate of transitions following initiation of PD and censored at time of death, kidney transplantation, transfer home hemodialysis, or administrative end of follow-up.
Measured: From PD initiation until 1-year after PD start Also assessed at from PD initation until 2- and 5-year after PD start.
Secondary outcomes (3)
All-cause mortality after transfer from peritoneal dialysis to hemodialysis
Censored for kidney transplantation, transfer home hemodialysis, return to PD or administrative end of follow-up December 31st, 2018
Measured: From first day after transfer up to 1-year post transfert. Also assessed ad 2- and 5-year post transfer
Return to Peritoneal Dialysis
Defined as ≥1 consecutive day of peritoneal dialysis after transition and censored at time of death, kidney transplantation, transfer home hemodialysis or administrative end of follow-up December 31st, 2018)
Measured: From first day after transfer to HD up to 180-day post transfer. Also measured at 90- and 365-day post transfer.
Transfer to Home Hemodialysis
Defined as ≥30 consecutive days of home hemodialysis censored at time of death, kidney transplantation, return to PD or administrative end of follow-up December 31st, 2018)
Measured: From first day after transfer to HD until 180-day post transfer. Also measured at 90- and 365-day post transfer
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Jan 2005
- Primary completion31 Dec 2019
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peritoneal Dialysis (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 17,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Annie-Claire Nadeau-Fredette, Ciusss de L'Est de l'Île de Montréal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07477210
- Sponsor's protocol ID
- 2021-2531
- Other IDs
- 203760_1
- Acronym
- UPLIFT-PD CORR
- Status last verified
- Mar 2026
- First submitted
- 20 Feb 2026
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Based on restriction from the Canadian Institute for Health Information and our third party agreement
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis, Epidemiology (Phase 1)
- ClinicalTrials.gov ID
- NCT07477210
- Acronym / sponsor ID
- UPLIFT-PD CORR / 2021-2531
- Keywords
- Transition, Transfer to hemodialysis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 17,000 participants (estimated)
- Lead sponsor
- Ciusss de L'Est de l'Île de MontréalUniversity, hospital or other
- Study start
- 1 Jan 2005 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- Dec 2027 (estimated)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Transitions from peritoneal dialysis to hemodialysis are common during kidney replacement therapy and may be associated with adverse outcomes. However, the incidence, predictors, and outcomes of PD-to-HD transitions at a national level remain incompletely characterized.
This study will use Canadian dialysis and hospitalization databases to examine the epidemiology and outcomes of PD-to-HD transitions among adults initiating dialysis in Canada. The study will evaluate transition incidence, predictors, and post-transition outcomes including mortality, transplantation, modality changes, and hospitalizations.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient receiving peritoneal dialysis with transfer to hemodialysis | – | –Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis and experience a transfer to hemodialysis for 2 or more consecutive days. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults initiating dialysis in Canada between 2005 and 2018 who received peritoneal dialysis for at least 30 consecutive days, identified using the Canadian Organ Replacement Register (CORR) and linked administrative databases.
Key inclusion criteria (3 listed)
- Adults (≥18 years)
- Dialysis initiation in Canada between January 1, 2005 and December 31, 2018
- Peritoneal dialysis duration >30 consecutive days
Key exclusion criteria (4 listed)
- Dialysis initiation in Quebec or Manitoba during the study period
- Dialysis initiation in a foreign country
- Missing data on initial dialysis modality
- Pre-emptive kidney transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of transfer from peritoneal dialysis to hemodialysis
Time frame: From PD initiation until 1-year after PD start Also assessed at from PD initation until 2- and 5-year after PD start.
Measured as cumulative incidence and incidence rate of transitions following initiation of PD and censored at time of death, kidney transplantation, transfer home hemodialysis, or administrative end of follow-up.
3 secondary outcomes
All-cause mortality after transfer from peritoneal dialysis to hemodialysis
Time frame: From first day after transfer up to 1-year post transfert. Also assessed ad 2- and 5-year post transfer
Return to Peritoneal Dialysis
Time frame: From first day after transfer to HD up to 180-day post transfer. Also measured at 90- and 365-day post transfer.
Transfer to Home Hemodialysis
Time frame: From first day after transfer to HD until 180-day post transfer. Also measured at 90- and 365-day post transfer
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
- Individual participant dataSharing planned: No. Based on restriction from the Canadian Institute for Health Information and our third party agreement
Related trials for Peritoneal Dialysis (PD)
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Not yet recruiting
Iodine Starch Test Use in Pleuroperitoneal Leak
Peritoneal Dialysis, Peritoneal Dialysis (PD)
RecruitingObservational study
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Kidney Disease, Peritoneal Dialysis (PD)
Recruiting
STarting incrEmental Prescription of Peritoneal Dialysis
Peritoneal Dialysis (PD), Kidney Failure
RecruitingObservational study
Peritoneal Dialysis Registration System (PERSIST)
ESRD, Disorders Associated With Peritoneal Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peritoneal Dialysis (PD) and Hemodialysis, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of transfer from peritoneal dialysis to hemodialysis (time frame: From PD initiation until 1-year after PD start Also assessed at from PD initation until 2- and 5-year after PD start.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.